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DCIS = ductal carcinoma in situ; kep = rate constant; Ktrans = transfer constant; MRI = magnetic resonance imaging; MVD = microvessel density;
ROI = region of interest; ve = extracellular, extravascular volume; VEGF = vascular endothelial growth factor.
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Introduction
The present review describes the use of MRI to evaluate
neoangiogenesis in breast tumours noninvasively. MRI is
now widely used to provide anatomical cross-sectional
images, with excellent definition of soft-tissue morphology.
For many applications, the technique has supplanted com-
puted tomography, particularly for imaging of the central
nervous system. Unlike conventional X-ray imaging or
computed tomography, which produce images that show
the X-ray attenuation of tissues, MRI measures the amount
of hydrogenous materials (water and lipid) in tissues. The
technique allows the appearance of images to be modu-
lated, allowing a range of different images to be obtained
from any given set of tissues. This ability to select and
manipulate the contrast between different tissues, as well
as to obtain image sections at any orientation, has led to a
rapidly growing range of clinical applications.
In imaging breast cancer, MRI is increasingly being used
in clinical problem solving, in situations in which X-ray
mammography is equivocal (due for example to dense
breast parenchyma, surgery or breast implants) and ultra-
sound is not informative. Many of the clinical applications
to date pertain to morphological evaluation, often based
on the use of contrast agents, which highlight areas with
increased vascular permeability. Such high-resolution
images enable sections through the breast to be
observed, typically providing full three-dimensional image
sets of both breasts, allowing identification of multifocal
and contralateral disease. Such images allow cancer to be
detected with high sensitivity, but may not distinguish
some benign conditions, particularly fibroadenoma, from
malignant disease.
More sophisticated MRI methods have recently been
developed that provide additional, functional information
about tumours. By observing the uptake and washout of
MRI contrast agents, malignant and benign disease can
be better discriminated. Using methods that involve mea-
surement of the transit of contrast through the vascular
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bed, and fitting the uptake and washout of contrast to
mathematical models of tissues, images of tissue perfu-
sion and contrast exchange between tissue and the vas-
cular bed can be calculated. These functional images aid
diagnosis, but also provide measures that relate to histo-
logical assessments of vascular density, providing a non-
invasive method for measuring angiogenesis. Such
techniques may help to identify those patients who would
benefit from antiangiogenic or antivascular treatments, and
are being evaluated as methods for assessing the
response to such treatments.
Tumour neoangiogenesis
As tumours develop, their metabolic demand for oxygen
and substrates exceeds the capacity of diffusion mecha-
nisms to deliver these substances. It is a necessary condi-
tion for further growth (above a few millimetres in
diameter) that the tumour develops supporting vasculature
[1••]. This is achieved by stress-induced release of growth
factors such as vascular endothelial growth factor (VEGF),
which can induce the development of a characteristically
permeable VEGF-dependent neovasculature. With contin-
ued growth, a disordered vascular structure develops,
which usually has a large blood volume and which may
contain vessels having differing degrees of maturity and
physiological control, together with varying perfusion and
levels of oxygenation. Maintaining this vascular structure is
a dynamic process, with regional changes in growth factor
expression in response to local conditions.
Angiogenesis is a complex process that is not yet fully
understood. Currently, it is principally assessed by
histopathological examination [2••], but MRI technology is
providing a promising noninvasive investigational tool.
Magnetic resonance imaging
MRI is a powerful technique for assessing soft tissues, allow-
ing imaging with high spatial resolution. Images comprise a
number of slices, which can be acquired in any orientation,
and which have a high spatial resolution in the plane (typi-
cally 0.5–2mm), with the slice thickness ranging from 3 to
8mm. Three-dimensional images can also be acquired by
employing thinner slices or isotropic resolution. MRI mea-
sures the signal from mobile hydrogen-containing molecules
in the body, with the mobility of the molecules modulating the
intensity of the signal. In the breast, MRI shows signal from
breast parenchyma (predominantly water) and from lipids,
the two signals having very different characteristics. By modi-
fying the way in which the MRI scanner performs the mea-
surements (the parameters of pulse sequences), the
appearance of tissues in images can be altered dramatically.
T1-weighted images show lipid as bright and parenchyma as
dark. Tumour also tends to be dark. T2-weighted images
show parenchyma as brighter than fat, and tumour also
tends to be bright. Recent reviews of MRI in breast cancer
[3•–5•] provide more detailed information.
MRI is intrinsically sensitive to movement, which provides
a powerful means to assess blood flow. This feature is
widely employed in several magnetic resonance angiogra-
phy techniques. One approach – time of flight angiogra-
phy – utilizes the difference in magnetization between a
slice of tissue being measured and blood flowing into the
slice, which allows visualization of major vessels. Another
approach – phase-contrast angiography – utilizes a
change in the properties of the magnetism as blood
moves in the presence of a gradient. These techniques are
most helpful in evaluating larger vessels, but the basic
techniques contribute to methods for assessing perfusion
and the self-diffusion of water. The sensitivity of magnetic
resonance angiography can be increased by using con-
trast agents.
Contrast-enhanced imaging
Advances in the application of MRI to breast cancer have
depended predominantly on the use of magnetic reso-
nance contrast agents to enhance the appearance of
lesions. The most widely used contrast agents are
chelates of gadolinium, a lanthanide with three unpaired
electrons that has a very strong magnetic field. Chelates
such as diaminotetra-ethyl penta-acetic acid (DTPA)
strongly bind the gadolinium, which avoids toxicity while
allowing access of water molecules to the gadolinium.
The strongly paramagnetic gadolinium has several effects.
It can change (relax) the magnetic state of hydrogen
atoms in water molecules; this markedly changes the
appearance of tissues, with a high contrast agent uptake
in T1-weighted images, causing tissues to appear bright.
High concentrations of gadolinium chelates can also
induce local changes in the magnetic field (magnetic sus-
ceptibility). This is most apparent during the first pass of a
bolus of contrast agent after rapid intravenous injection.
On gradient echo T2*-weighted images, this effect is
apparent as a darkening of the image in well-perfused
areas of tissue.
Dynamic measurements, in which the uptake and washout
of contrast in tissues is monitored with time, can assist in
the diagnosis of breast tumours and can provide informa-
tion on vascular permeability and perfusion, by quantifying
and analyzing image intensity changes, and fitting these to
analytical or model functions. Considerable effort is being
devoted to the development of new contrast agents;
macromolecular agents, which exhibit lower vascular per-
meability or are limited to the blood pool, are currently
being developed and used in preclinical research. Agents
that use superparamagnetic or ferrite particles cause large
T2* signal losses, and are also being investigated. An area
that will grow in importance is the use of agents based on
the above approaches that can report on the cellular
expression of specific receptors, transfected genes or
oncogenes.Breast Cancer Research    Vol 3 No 1 Leach
Conventional diagnosis of breast disease utilizes informa-
tion on contrast-enhanced morphology and on the dynamic
behaviour of the contrast agent. T1-weighted multislice
sequences, or three-dimensional sequences, provide
spatial information, but there is usually a trade off between
spatial and temporal resolution. Information from both
approaches has been used for diagnosis, with a develop-
ing consensus that a combination of morphology and
dynamic information will maximize specificity [6•]. Morpho-
logical information identifies areas of permeable vascula-
ture, showing the way in which these areas relate to normal
breast architecture, and certain benign and malignant
lesions have characteristic appearances. Fig. 1 shows an
example of an infiltrating ductal carcinoma in a 50-year-old
woman, which shows characteristic rim enhancement.
Dynamic information shows the rate at which tissue
enhances, and subsequently the rate at which contrast
agent washes out. This depends on delivery of the agent
(perfusion), the ability of the agent to leak out of the vascula-
ture (vascular permeability), and the extracellular, extravas-
cular volume (ve – the capacity of the tissue to take up
contrast agent). Thus, the contrast agent provides a non-
invasive probe of the tissue vasculature, a critical aspect of
tumour architecture and regulation. Usually, a region of
interest (ROI) is selected within the tumour, and the soft-
ware that is provided with the magnetic resonance scanner
is used to evaluate the change in signal intensity with time in
that ROI. Often, if three-dimensional imaging is employed,
images are taken at intervals of typically 90s. Permeable,
well-perfused tissues exhibit a rapid rise in contrast, fol-
lowed by evidence of washout by 4–5 min after bolus injec-
tion. This is highly suggestive of malignant disease, although
some fibroadenomas can show similar features.
Although they aid diagnosis, simple T1-weighted images
do not provide quantitative information, and cannot be
used directly in models to obtain quantitative parameters
that describe uptake.
Quantitative techniques [7•] that are often combined with
rapid temporal sampling have been used, together with
simple compartmental models of tissues, to obtain parame-
ters such as ve, the transfer constant (Ktrans) and the rate
constant (kep) [8•]. These latter two parameters combine
information on perfusion and tissue permeability, and provide
a way to assess the ‘leakiness’ of vasculature, which is
believed to reflect the degree of angiogenesis within the
tumour. Ktrans describes the flux of contrast agent through
the vascular endothelium. If delivery to ve is not limited by
perfusion (ie delivery to the endothelium) but by the leakiness
of the endothelium, then Ktrans is the capillary endothelial per-
meability surface area product, describing vascular perme-
ability. However, if delivery is limited by perfusion, then when
permeability is high Ktrans is equal to the blood plasma flow
per unit volume of tissue. Thus, high values of Ktrans indicate
high permeability and probably high perfusion. Low values of
Ktrans indicate either low permeability and/or low perfusion.
The constant kep describes the flux of contrast agent
between ve and the blood plasma, and is equal to Ktrans/ve.
The accuracy of these parameters in monitoring vascular
properties depends on whether quantitative imaging tech-
niques that allow T1 to be calculated are used. When
obtained with such methods, these parameters relate
closely to tissue properties and are independent of imaging
methods and instruments used. However, they are not
solely dependent on vascular endothelial permeability, and
this needs to be borne in mind when interpreting results.
Recent developments have allowed these parameters to
be mapped on a pixel-by-pixel basis, providing a colour
parametric image and allowing a description of the varia-
tion in tumour vasculature throughout the tumour [9]. This
is likely to be a more informative approach than taking a
tumour average of these parameters or performing a ROI
analysis to assess prognosis and response.
Clinical studies that correlate dynamic
parameters with histopathology
Several studies have examined the correlation between
dynamic imaging parameters and histopathological
Figure 1
A T1-weighted postcontrast image from a three-dimensional fat-
suppressed sequence, showing distinctive rim enhancement.
Reprinted from Magn Reson Imaging, volume 18, Brown et al,
Magnetic resonance imaging screening in women at genetic risk of
breast cancer: imaging and analysis protocol for the UK multicentre
study, pp 765–776. Copyright 2000, with permission from Elsevier
Science.Available online http://breast-cancer-research.com/content/3/1/022
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assessment. Buckley et al [10] compared simple indices
of enhancement and parameters from a two-compart-
mental model with microvessel density (MVD). A signifi-
cant correlation was found between initial enhancement
in the maximally enhancing ROI and MVD (P=0.002),
and this correlation was stronger in node-positive
tumours. A similar study in 73 patients [11] found asso-
ciations between slope of uptake and MVD (P<0.001)
and between MVD grade and curve type (P<0.001).
Frouge et al [12] compared dynamic MRI with quantifica-
tion of tumour angiogenesis by immunohistological staining
in 20 patients with small palpable lumps. After excluding
patients with motion artefacts, poor alignment with histol-
ogy, and benign and nonbreast-originating disease, nine
patients were evaluable. One of these showed no contrast
enhancement. Factor analysis identified three separable
enhancement components, of which the first peaked at
40s after injection and fell rapidly, and the second peaked
at 2 min and decreased more slowly. In four patients, early
enhancement (the first factor) was found to correlate with a
high concentration of arterioles or intratumour repair
processes. In eight patients the second factor was associ-
ated with tumour capillaries. The third factor also reached a
maximum at about 2 min, but did not then decrease; this
was seen in three women and was associated with fibrosis.
A study in 44 women with invasive breast cancer [13] com-
pared dynamic contrast-enhanced measurements with his-
tological assessment of microvessel density using staining
with anti-CD34 antibody. The authors found increased
microvessel density in the periphery of the tumours, and
reported that enhancement correlated with microvessel
density and that there was a significant association
between histological grade and both the steepest part of
the uptake curve and microvessel density. However, it
should be noted that the limited time resolution (90s) for
each of the three three-dimensional images provides
limited scope for differentiating different uptake rates.
Stomper  et al [14] compared enhancement parameters
with factor VIII staining and vessel density measurement in
48 breast lesions following excisional biopsy. Vessel den-
sities in 25 malignant lesions were not significantly differ-
ent on histological evaluation from those in 23 benign
lesions. Seven out of the eight fibroadenomas had high
vessel density. Higher vessel density was associated with
increased contrast uptake (P=0.02), but the rate and
washout of enhancement showed no significant associa-
tion with vessel density. This is in accord with the limited
discrimination of contrast enhancement dynamics
between malignant and benign (particularly fibroadenoma)
disease. The MRI measurement and analysis technique
employed in that study might have been biased by precon-
trast lesion T1, and had limited time resolution. No model-
ling parameters were derived.
Knopp et al [15•] compared histological parameters (vas-
cular density using CD31, vascular permeability using
VEGF) with enhancement parameters. They were able to
show a dependence of enhancement kinetics on VEGF
expression, and demonstrated differences in enhancement
parameters between different histological tumour types
and between malignant and benign disease.
Seventy-one breast lesions were investigated [16] using
echo-planar imaging to calculate extraction-flow products,
but no significant correlation between MVD and extrac-
tion-flow product was identified. Echo-planar imaging is
not widely used in breast imaging.
Early enhancement in 36 women with ductal carcinoma in
situ (DCIS) was investigated [17]. Angiogenesis in the
stroma surrounding ducts (as demonstrated by
immunoperoxidase staining) was shown to correlate with
early contrast enhancement in 34 patients with DCIS, but
not in two with comedo-type DCIS.
Experimental studies of dynamic enhanced
contrast uptake
Modelling parameters have been obtained [18•,19••] using
the Tofts and Kermode model (Ktrans, ve) in an MCF7
human breast cancer xenograft in nude mice. High values
of Ktrans were found in regions that histologically demon-
strated a high density of permeable microcapillaries; these
regions were in the tumour periphery and in intratumoural
regions that surrounded areas of necrosis. This was
believed to represent stress-induced angiogenesis. This
induction of angiogenesis was augmented on treatment
with tamoxifen.
The same group [20] also used the MCF7 tumour line,
together with a three-point assessment of contrast agent
uptake, to show that tamoxifen treatment increased the
number of voxels that displayed rapid contrast uptake and
the number of voxels that showed intermediate clearance
(ie a plateau phase). This was believed to result from
increased extracellular volume and increased microvascu-
lar permeability, which those investigators considered to
result from increased necrosis and stress-induced angio-
genesis, respectively.
Targeted contrast agents
Pham et al [21] have reported on the use of macromolec-
ular contrast medium-enhanced MRI to monitor the
effects of anti-VEGF antibody in MDA-MB-435 human
breast cancer cells implanted into nude rats. The anti-
VEGF antibody was shown to reduce MRI-assessed
microvascular permeability.
A novel approach using a novel synthetic protected graft
copolymer as a vascular probe in MCF-7 human breast
cancer cell line and MCF-7 cells transfected with theBreast Cancer Research    Vol 3 No 1 Leach
cDNA for the VEGF165 isoform (MV165) in nude mice has
been reported [22]. The protected graft copolymer agent
showed enhanced vascular fraction in the transfected cell
line, which was confirmed on histology, showing the poten-
tial of this approach to image angiogenesis specifically.
Sipkins et al [23] report a further experimental approach
to imaging a specific angiogenic marker, a paramagnetic
contrast agent that was targeted to endothelial aVb3 via
the LM609 monoclonal antibody, in a rabbit model. This
provided high-resolution imaging of rabbit carcinoma.
Assessing response to treatment
Little has been published on assessing response to treat-
ment of breast cancer using dynamic contrast-enhanced
methods. Preliminary reports have shown that Ktrans pro-
vides an early measure of response to primary medical
therapy, with responding tumours showing a reduction in
the range of Ktrans and a reduction in median Ktrans. Non-
responding tumours predominantly showed an increasing
range of Ktrans values; in well-perfused tissues this
reflected changes in the microvascular permeability [24].
These techniques have also been employed in a phase 1
clinical trial of a VEGF inhibitor [25], in which tumours that
exhibited stasis showed a reduction in Ktrans.
Conclusion
MRI provides powerful methods for investigating vascular
changes associated with neoangiogenesis. These are
already gaining currency in diagnosis, and are now being
evaluated with regard to their ability to assess tumour
response to treatment. Clinical comparisons with
histopathology have shown that rapid enhancement is
associated with microvascular density. Also, animal
studies and one clinical study have demonstrated an asso-
ciation between VEGF and model parameters such as
Ktrans and kep, reflecting the increased permeability of neo-
vasculature. In one clinical study benign and malignant
lesions with similar distributions of MVD on histology
could not be distinguished on the basis of contrast
enhancement, although the amplitude, but not the rate, of
contrast enhancement correlated with MVD. A further
study using the technique of echo-planar imaging also
showed no correlation with MVD.
Although the weight of evidence indicates that correla-
tions between MRI and histological measures of vascula-
ture can be obtained, there is clearly some variation. This
is likely to be due to the considerable variation in the MRI
approaches used during the development phase of this
new application, and emphasizes the need for standard-
ization in MRI measurement and analysis. It is likely that
new contrast agents and improvements in measurement
and analytic methods will further extend the utility of MRI in
investigating the vascular dependence of tumour growth
and the activity of vascular-directed therapies.
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